文献速递心血管技术与安全SPECTCT

接受治疗的转甲状腺素蛋白淀粉样心肌病患者系列骨闪烁显像结果临床相关性不确定

Uncertain Clinical Relevance of Serial Bone Scintigraphy Findings in Treated Transthyretin Amyloid Cardiomyopathy.
PubMed 文献 · JACC Cardiovasc Imaging · 2025-07-09

回顾性多模态影像研究纳入66例接受淀粉样特异性疾病修饰治疗的转甲状腺素蛋白淀粉样心肌病患者,比较治疗前后99mTc-DPD显像心肌注射剂量百分比变化与超声心动图、生化及心脏磁共振参数变化的相关性。随访中位27.5个月,心肌注射剂量百分比平均降低1.5%±1.5%,但与各已验证标志物变化均无统计学显著相关,42.4%患者显像改善却疾病进展。

要点

  • ATTR-CM患者接受疾病修饰治疗后,99mTc-DPD心肌摄取降低与超声、生化及CMR指标变化无显著相关。
  • 42.4%(28/66)患者随访99mTc-DPD显像改善但疾病进展,二者不一致。
  • 作者认为DPD摄取变化在治疗随访中应谨慎解读。

核心结论

  • 研究显示随访时99mTc-DPD心肌摄取降低与多个ATTR-CM治疗反应的既定生物标志物之间相关性差。

研究设计与样本

  • 回顾性多模态影像研究,纳入英国国家淀粉样变性中心66例接受淀粉样特异性疾病修饰治疗并完成治疗前后99mTc-DPD/SPECT-CT扫描的ATTR-CM患者,测量基线及随访心肌注射剂量百分比(PID),并与超声心动图、生化及心脏磁共振参数变化比较。

关键影像表现/征象

  • 99mTc-DPD显像心肌PID代表心脏淀粉样负荷的闪烁显像指标,在治疗前后系列扫描中测量。
  • 随访中位27.5个月(Q1-Q3:21.9-33.1个月),心肌PID较治疗前平均降低1.5%±1.5%。

临床应用与阅片要点

  • 作者认为,接受疾病修饰治疗的ATTR-CM患者中DPD摄取变化应谨慎解读。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Technetium-99m-labeled 3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD) scintigraphy is a critical part of the validated nonbiopsy diagnostic algorithm for transthyretin amyloid cardiomyopathy (ATTR-CM). With the advent of novel disease-modifying therapies for ATTR-CM, there is intense interest in establishing the utility of DPD scans as an indicator of treatment response.

OBJECTIVES: The authors conducted a retrospective multimodality imaging study to determine the utility of 99mTc-DPD to track treatment response in ATTR-CM.

METHODS: ATTR-CM patients from the United Kingdom National Amyloidosis Centre who were receiving amyloid-specific disease-modifying therapy (DMT) and underwent pre- and post-treatment 99mTc-DPD/single-photon emission computed tomography-computed tomography scans were included. Myocardial percentage injected dose (PID), a proposed scintigraphic indicator of cardiac amyloid burden, was measured at baseline and follow-up. Change from baseline in this variable was compared with that of other validated biomarkers of disease severity.

RESULTS: A total of 66 patients with ATTR-CM who received DMT underwent serial 99mTc-DPD scans. At follow-up, with a median time between 99mTc-DPD scans of 27.5 months (Q1-Q3: 21.9-33.1 months), there was a mean reduction from pre-DMT myocardial PID on 99mTc-DPD scintigraphy of 1.5 ± 1.5%. No statistically significant correlation between the change in PID at follow-up and change in echocardiographic, biochemical, or cardiac magnetic resonance parameters was identified. Discordance in which there was an improvement on follow-up 99mTc-DPD scintigraphy despite disease progression was observed in 28/66 patients (42.4%).

CONCLUSIONS: Our study indicates a poor correlation between reduction in 99mTc-DPD uptake at follow-up and numerous established biomarkers of ATTR-CM treatment response. Changes in DPD uptake in ATTR-CM patients receiving DMT should be interpreted with caution.

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Razvi Y, Porcari A, Hutt DF, et al. Uncertain Clinical Relevance of Serial Bone Scintigraphy Findings in Treated Transthyretin Amyloid Cardiomyopathy. JACC Cardiovasc Imaging. 2025. PMID: 40637650. doi:10.1016/j.jcmg.2025.03.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。